Acadia Pharmaceuticals shares plunge as Parkinson’s disease drug fails late-stage studyAcadia shares fall on failed Parkinson’s study NEW YORK — Shares of Acadia Pharmaceuticals Inc. plunged Tuesday after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson’s disease psychosis. Tips for women travelers: Don’t forget the dental flossTips for women travelers: Don’t forget the floss CAMBRIDGE, Mass. — What do dental floss, shower caps and Bounce dryer sheets have in common? Shorter treatments, fewer visits; spa-goers find ways to pamper themselves in tough timesGo less, shorten treatments to hold on to the spa NEW YORK — In this economy, we could probably all use a little pampering: a massage, a facial, a pedicure. Perhaps a nice soak in a hot whirlpool. Study shows experimental drug cuts stroke risk in patients with irregular heartbeatsStudy shows experimental drug cuts stroke risk BARCELONA, Spain — An experimental drug reduces the stroke risk in patients with irregular heartbeats by more than three times, compared with the popular drug warfarin — but possibly at a cost, according to new research released Sunday. FDA cites shortcomings with Genzyme study of leukemia drug for frail, elderly patientsFDA: problems with Genzyme study of leukemia drug WASHINGTON — Federal regulators on Friday questioned whether Genzyme’s leukemia drug Clolar should be approved for older patients based on limited studies conducted by the biotech drugmaker. |
|